JP2011251985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011251985A5 JP2011251985A5 JP2011157930A JP2011157930A JP2011251985A5 JP 2011251985 A5 JP2011251985 A5 JP 2011251985A5 JP 2011157930 A JP2011157930 A JP 2011157930A JP 2011157930 A JP2011157930 A JP 2011157930A JP 2011251985 A5 JP2011251985 A5 JP 2011251985A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- pharmaceutically acceptable
- acceptable salt
- hydroxamic acid
- batch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 6
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 6
- 229960000237 vorinostat Drugs 0.000 claims 6
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003931 anilides Chemical class 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68287505P | 2005-05-20 | 2005-05-20 | |
| US60/682,875 | 2005-05-20 | ||
| US69312805P | 2005-06-23 | 2005-06-23 | |
| US60/693,128 | 2005-06-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540436A Division JP5264174B2 (ja) | 2005-05-20 | 2006-05-16 | スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011251985A JP2011251985A (ja) | 2011-12-15 |
| JP2011251985A5 true JP2011251985A5 (enExample) | 2012-10-04 |
| JP5308486B2 JP5308486B2 (ja) | 2013-10-09 |
Family
ID=37452585
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540436A Active JP5264174B2 (ja) | 2005-05-20 | 2006-05-16 | スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 |
| JP2011157930A Active JP5308486B2 (ja) | 2005-05-20 | 2011-07-19 | スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540436A Active JP5264174B2 (ja) | 2005-05-20 | 2006-05-16 | スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8093295B2 (enExample) |
| EP (2) | EP2292221A3 (enExample) |
| JP (2) | JP5264174B2 (enExample) |
| KR (2) | KR100993135B1 (enExample) |
| AR (1) | AR055953A1 (enExample) |
| AU (3) | AU2006249440C1 (enExample) |
| BR (1) | BRPI0605893A (enExample) |
| CA (1) | CA2580367C (enExample) |
| CR (1) | CR8912A (enExample) |
| DO (1) | DOP2006000113A (enExample) |
| EC (1) | ECSP077263A (enExample) |
| IL (1) | IL181070A0 (enExample) |
| MA (1) | MA28804B1 (enExample) |
| MX (1) | MX2007002047A (enExample) |
| MY (1) | MY144613A (enExample) |
| NI (1) | NI200700031A (enExample) |
| NZ (2) | NZ594669A (enExample) |
| PE (1) | PE20061390A1 (enExample) |
| TW (2) | TWI365068B (enExample) |
| WO (2) | WO2006127319A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI365068B (en) * | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| NZ592686A (en) | 2008-10-15 | 2012-12-21 | Generics Uk Ltd | Process for the preparation of vorinostat from aniline, hydroxylamine and suberic acid starting materials |
| WO2010061220A2 (en) * | 2008-11-26 | 2010-06-03 | Generics [Uk] Limited | Novel processes and pure polymorphs |
| CN102282126A (zh) * | 2008-11-26 | 2011-12-14 | 基因里克斯(英国)有限公司 | 多晶型物 |
| US20110313044A1 (en) * | 2010-06-18 | 2011-12-22 | Urquima S.A. | Polymorphs of Suberoylanilide Hydroxamic Acid |
| WO2018011811A2 (en) * | 2016-07-13 | 2018-01-18 | Rappaport Family Institute For Research In The Medical Sciences | Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification |
| CN107362148B (zh) * | 2017-07-27 | 2020-04-21 | 东曜药业有限公司 | 一种治疗肿瘤的药物组合物及其制备方法和应用 |
| EP4007585A4 (en) | 2019-08-02 | 2023-11-08 | OneHealthCompany, Inc. | TREATMENT OF CANINE CANCERS |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS61176523A (ja) | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
| US5608108A (en) | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| USRE38506E1 (en) | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5700811A (en) | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| JP3170069B2 (ja) * | 1992-10-06 | 2001-05-28 | 日水製薬株式会社 | 徐放性顆粒剤 |
| US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
| US6043389A (en) | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| US6124495A (en) | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
| US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| US6262116B1 (en) | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| KR20010080142A (ko) | 1998-10-13 | 2001-08-22 | 후지야마 아키라 | 사이클릭 테트라펩티드 화합물 및 이의 용도 |
| KR20020007398A (ko) | 1999-05-03 | 2002-01-26 | 추후제출 | 히스톤 탈아세틸화효소의 억제 |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| BR0014254A (pt) | 1999-09-08 | 2002-08-27 | Sloan Kettering Inst Cancer | Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos |
| KR20070053362A (ko) | 1999-11-23 | 2007-05-23 | 메틸진, 인크. | 히스톤 디아세틸라제의 억제제 |
| ATE489360T1 (de) | 2000-03-24 | 2010-12-15 | Methylgene Inc | Inhibitoren der histon-deacetylase |
| AU2001285042A1 (en) | 2000-08-18 | 2002-03-04 | The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| NZ525439A (en) | 2000-09-29 | 2004-11-26 | Topotarget Uk Ltd | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
| US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2002102323A2 (en) | 2001-06-14 | 2002-12-27 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
| JP4638148B2 (ja) | 2001-10-16 | 2011-02-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 神経変性疾患および脳の癌の処置 |
| US20040132643A1 (en) | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| AU2003219803B8 (en) | 2002-02-15 | 2005-08-25 | Sloan-Kettering Institute For Cancer Research | Method of treating TRX mediated diseases |
| US20070060614A1 (en) | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US20060276547A1 (en) | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| EP2266552A3 (en) | 2002-03-04 | 2011-03-02 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| CN100566711C (zh) | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
| DE10218106A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
| EP1567142A4 (en) | 2002-11-20 | 2005-12-14 | Errant Gene Therapeutics Llc | TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS |
| CN1839121A (zh) | 2003-04-01 | 2006-09-27 | 斯隆-凯特林癌症研究所 | 异羟肟酸化合物及其使用方法 |
| CA2535806C (en) * | 2003-08-26 | 2009-02-17 | Aton Pharma, Inc. | The use of hdac inhibitors for the treatment of cancer |
| TWI365068B (en) * | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| US20090227674A1 (en) | 2005-08-18 | 2009-09-10 | Richon Victoria M | Combination methods fo saha and targretin for treating cancer |
| EP1942884A4 (en) | 2005-11-04 | 2010-01-06 | Merck & Co Inc | METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES |
| CN101300015A (zh) | 2005-11-04 | 2008-11-05 | 默克公司 | 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法 |
| US20070197473A1 (en) | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
-
2006
- 2006-05-11 TW TW095116824A patent/TWI365068B/zh not_active IP Right Cessation
- 2006-05-11 TW TW099119337A patent/TWI415603B/zh not_active IP Right Cessation
- 2006-05-15 DO DO2006000113A patent/DOP2006000113A/es unknown
- 2006-05-16 EP EP10183861A patent/EP2292221A3/en not_active Withdrawn
- 2006-05-16 WO PCT/US2006/018737 patent/WO2006127319A2/en not_active Ceased
- 2006-05-16 BR BRPI0605893-0A patent/BRPI0605893A/pt not_active IP Right Cessation
- 2006-05-16 NZ NZ594669A patent/NZ594669A/xx not_active IP Right Cessation
- 2006-05-16 NZ NZ553204A patent/NZ553204A/en not_active IP Right Cessation
- 2006-05-16 US US11/663,165 patent/US8093295B2/en active Active
- 2006-05-16 JP JP2007540436A patent/JP5264174B2/ja active Active
- 2006-05-16 CA CA2580367A patent/CA2580367C/en active Active
- 2006-05-16 WO PCT/US2006/018795 patent/WO2006127321A2/en not_active Ceased
- 2006-05-16 PE PE2006000515A patent/PE20061390A1/es not_active Application Discontinuation
- 2006-05-16 KR KR1020087030074A patent/KR100993135B1/ko not_active Expired - Fee Related
- 2006-05-16 KR KR1020077003998A patent/KR100884500B1/ko not_active Expired - Fee Related
- 2006-05-16 EP EP06759843A patent/EP1853245A2/en not_active Ceased
- 2006-05-16 MX MX2007002047A patent/MX2007002047A/es active IP Right Grant
- 2006-05-16 AU AU2006249440A patent/AU2006249440C1/en active Active
- 2006-05-17 AR ARP060101986A patent/AR055953A1/es not_active Application Discontinuation
- 2006-05-17 MY MYPI20062258A patent/MY144613A/en unknown
-
2007
- 2007-01-30 IL IL181070A patent/IL181070A0/en unknown
- 2007-02-02 NI NI200700031A patent/NI200700031A/es unknown
- 2007-02-07 CR CR8912A patent/CR8912A/es unknown
- 2007-02-16 EC EC2007007263A patent/ECSP077263A/es unknown
- 2007-02-16 MA MA29685A patent/MA28804B1/fr unknown
-
2009
- 2009-04-27 AU AU2009201650A patent/AU2009201650B2/en not_active Ceased
- 2009-04-27 AU AU2009201652A patent/AU2009201652B2/en not_active Ceased
-
2010
- 2010-01-13 US US12/686,812 patent/US8288440B2/en active Active
- 2010-01-13 US US12/686,843 patent/US8450372B2/en active Active
- 2010-01-13 US US12/686,830 patent/US20100113829A1/en not_active Abandoned
-
2011
- 2011-07-19 JP JP2011157930A patent/JP5308486B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011251985A5 (enExample) | ||
| WO2013132457A3 (en) | Nanocrystalline solid dispersion compositions and process of preparation thereof | |
| CL2013000347A1 (es) | Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion. | |
| JP2014515013A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2015145426A5 (enExample) | ||
| JP2013527475A5 (enExample) | ||
| JP2012067110A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2012524724A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2012132799A5 (enExample) | ||
| JP2015525757A5 (enExample) | ||
| JP2014167010A5 (enExample) | ||
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| JP2014218522A5 (enExample) | ||
| JP2013007118A5 (enExample) | ||
| JP2014097964A5 (enExample) | ||
| TN2012000435A1 (en) | Agomelatine hydrochloride hydrate and preparation thereof | |
| CA2899024C (en) | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid | |
| WO2012146980A3 (en) | Preparation of fingolimod and its salts | |
| JP2017505809A5 (enExample) | ||
| CR8912A (es) | Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas | |
| JP2012051888A5 (enExample) |